Terms: = Prostate cancer AND ETV4, PEA3, 2118, ENSG00000175832, E1AF, E1A-F, PEAS3 AND Prognosis
5 results:
1. Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.
Hellwege JN; Stallings S; Torstenson ES; Carroll R; Borthwick KM; Brilliant MH; Crosslin D; Gordon A; Hripcsak G; Jarvik GP; Linneman JG; Devi P; Peissig PL; Sleiman PAM; Hakonarson H; Ritchie MD; Verma SS; Shang N; Denny JC; Roden DM; Velez Edwards DR; Edwards TL
Sci Rep; 2019 Apr; 9(1):6077. PubMed ID: 30988330
[TBL] [Abstract] [Full Text] [Related]
2. Overexpression of etv4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Qi M; Liu Z; Shen C; Wang L; Zeng J; Wang C; Li C; Fu W; Sun Y; Han B
Tumour Biol; 2015 May; 36(5):3565-72. PubMed ID: 25544710
[TBL] [Abstract] [Full Text] [Related]
3. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.
Zhang S; Pavlovitz B; Tull J; Wang Y; Deng FM; Fuller C
Diagn Mol Pathol; 2010 Sep; 19(3):151-6. PubMed ID: 20736744
[TBL] [Abstract] [Full Text] [Related]
4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and pea3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract] [Full Text] [Related]
5. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Gavrilov D; Kenzior O; Evans M; Calaluce R; Folk WR
Eur J Cancer; 2001 May; 37(8):1033-40. PubMed ID: 11334730
[TBL] [Abstract] [Full Text] [Related]
